ArticleBone & joint research2026
An analysis of the cytokine profile of platelet-rich plasma when combined in vitro with low versus high molecular weight hyaluronic acid.
Article in Bone & joint research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Aims: Platelet-rich plasma (PRP) and hyaluronic acid (HA) are nonoperative treatments for osteoarthritis (OA) of large joints. Clinically, some endorse the use of both methods together for a theoretical synergistic effect therapeutically, with limited evidence. This study aimed to evaluate whether the molecular weight of HA influences the cytokines released from PRP in vitro. Methods: Leucocyte-rich PRP was prepared from venous blood of ten healthy males (aged 18 to 35 years). Three groups were tested: PRP + phosphate-buffered saline (PBS, control), PRP + low molecular weight HA (LMWHA, and PRP + high molecular weight HA (HMWHA). Samples were incubated at 37°C, and the concentrations of insulin-like growth factor binding protein 1 (IGFBP1), interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1RA), IL-6, IL-10, platelet-derived growth factor subunit B (PDGF-BB), transforming growth factor-β (TGF-β1), and tumour necrosis factor-alpha (TNF-α) were measured at two hours (Day 0) and 72 hours (Day 3). Data were analyzed using repeated measures analysis of variance (p < 0.05). A Bonferroni test was performed as a post hoc analysis. Results: PDGF-BB decreased significantly (p < 0.001) from Day 0 to 3 across all groups. This was more pronounced in the presence of HA, regardless of molecular weight. IL-1β rose significantly in HA-treated groups only (p = 0.009). No significant intergroup differences emerged for IGFBP1, IL-6, TGF-β1, or TNF-α at either timepoint. There was a significant increase in both IL-1RA (p = 0.016), and IL-10 (p < 0.001) concentration from Day 0 to 3. There were no significant differences in IL-1RA or IL-10 between the control, LMWHA, and HMWHA groups at Day 0 or 3. Conclusion: The molecular weight of HA did not improve the cytokine profile of PRP in vitro, suggesting that both LMWHA and HMWHA formulations may be comparable when used in combination with PRP, at least in males.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.